This inventor holds 2 USPTO granted patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Akiyoshi Kunugi: Innovator in Antisense Oligonucleotide Technology
Introduction
Akiyoshi Kunugi is a prominent inventor based in Fujisawa, Japan. He has made significant contributions to the field of molecular biology, particularly in the development of antisense oligonucleotides. His work focuses on innovative methods for splicing modulation, which has important implications for treating various diseases.
Latest Patents
Akiyoshi Kunugi holds a patent for "Compositions and methods for splicing modulation of UNC13A." This patent describes antisense oligonucleotides designed to inhibit the inclusion of a cryptic exon into the mature mRNA of UNC13A. The patent also includes pharmaceutical compositions that utilize these oligonucleotides and outlines methods for treating UNC13A-associated diseases or conditions related to TDP-43 dysfunction.
Career Highlights
Kunugi is affiliated with Takeda Pharmaceutical Company Limited, where he continues to advance his research and development efforts. His work has been instrumental in exploring new therapeutic avenues for complex diseases, showcasing his commitment to innovation in the pharmaceutical industry.
Collaborations
Akiyoshi Kunugi collaborates with Masahiro Nogami, contributing to the advancement of their shared research interests. Their partnership exemplifies the collaborative spirit that drives innovation in scientific research.
Conclusion
Akiyoshi Kunugi is a key figure in the field of antisense oligonucleotide technology, with a focus on splicing modulation. His contributions have the potential to impact the treatment of significant medical conditions, highlighting the importance of innovation in healthcare.